Pay in 4 interest-free payments of $5.11 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Lillys eloralintide (amylin receptor agonist), providing a potential option for Lilly to defend against amylin analogues, including Novo Nordisks CagriSema, which combines dual amylin and calcitonin receptor agonist cagrilintide and semaglutide, or Zealands petrelintide (phase 2) Structure Therapeutics GSBR-1290 (GLP-1), small molecule, oral obesity therapy, seeking to substantiate its earlier, positive phase 2a data to deliver competitive weight loss, against both other oral therapies and marketed injectables, with acceptable tolerability (phase 2b) Crucially, a number of phase 3 readouts in 2025 for key AOM assets will set the stage for their launch in 2026, when the next wave of AOMs enter the market to re-shape the competitive landscape: Lillys orforglipron (GLP-1), one of the first oral AOMs to launch, possibly alongside oral semaglutide, and when it does, the first small molecule based therapy in the market
Oral semaglutide has much lower bioavailability (the amount that actually reaches your bloodstream) than the injectable form, because the digestive system degrades proteins
Max dosing requires 2mL (1 vial) per month
J Endocrinol , 2000;165(3):56977
Even two to three sessions per week of basic resistance exercises significantly reduces lean mass loss compared to tirzepatide treatment without exercise
Keep in mind that GLP-1 injectables lose effectiveness if theyre not stored at the correct temperature, which makes proper handling and sourcing essential
